K
Kazuyoshi Saito
Researcher at University of Occupational and Environmental Health Japan
Publications - 267
Citations - 6847
Kazuyoshi Saito is an academic researcher from University of Occupational and Environmental Health Japan. The author has contributed to research in topics: Rheumatoid arthritis & Lupus erythematosus. The author has an hindex of 46, co-authored 252 publications receiving 6041 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Mikiko Tokunaga,Kazuyoshi Saito,Daisuke Kawabata,Yoshitaka Imura,Takao Fujii,Shingo Nakayamada,Shizuyo Tsujimura,Masao Nawata,Shigeru Iwata,Taeko Azuma,Tsuneyo Mimori,Yoshiya Tanaka +11 more
TL;DR: Rituximab rapidly improved refractory NPSLE, as evident by resolution of various clinical signs and symptoms and improvement of radiographic findings, and the down regulation of functional molecules on B and T cells suggests that ritUXimab modulates the interaction of activated B andT cells through costimulatory molecules.
Journal ArticleDOI
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Yoshiya Tanaka,Tsutomu Takeuchi,Tsuneyo Mimori,Kazuyoshi Saito,Masao Nawata,Hideto Kameda,Takaki Nojima,Nobuyuki Miyasaka,Takao Koike +8 more
TL;DR: After attaining LDA by infliximab, 56 (55%) of the 102 patients with RA were able to discontinue inflIXimab for >1 year without progression of radiological articular destruction.
Journal ArticleDOI
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells
Keisuke Maeshima,Kunihiro Yamaoka,Satoshi Kubo,Kazuhisa Nakano,Shigeru Iwata,Kazuyoshi Saito,Masanobu Ohishi,Hisaaki Miyahara,Shinya Tanaka,Koji Ishii,Hironobu Yoshimatsu,Yoshiya Tanaka +11 more
TL;DR: Tofacitinib directly suppressed the production of IL-17 and IFNγ and the proliferation of CD4+ T cells, resulting in inhibition ofIL-6 production by RASFs and IL-8 production by CD14+ cells and decreased cartilage destruction.
Journal Article
CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins
Takeshi Fujisaki,Yoshiya Tanaka,Koichi Fujii,Shinichiro Mine,Kazuyoshi Saito,Shinwa Yamada,Uki Yamashita,Tatsuro Irimura,Sumiya Eto +8 more
TL;DR: The results indicated that stimulation by CD44 induces "outside-in signaling," which consists of a direct pathway via CD44 and an alternate pathway through the induction of c-Met expression via HGF, which leads to amplification of integrin-mediated adhesion to the vessel wall and subsequent transendothelial migration.
Journal ArticleDOI
Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.
Yukiko Komano,Masayoshi Harigai,Ryuji Koike,Haruhito Sugiyama,Jun Ogawa,Kazuyoshi Saito,Naoya Sekiguchi,Masayuki Inoo,Ikuko Onishi,Hiroyuki Ohashi,Fujio Amamoto,Masayuki Miyata,Hideo Ohtsubo,Kazuko Hiramatsu,Masahiro Iwamoto,Seiji Minota,Naoki Matsuoka,G. Kageyama,Kazuyoshi Imaizumi,Hitoshi Tokuda,Yasumi Okochi,Koichiro Kudo,Yoshiya Tanaka,Tsutomu Takeuchi,Nobuyuki Miyasaka +24 more
TL;DR: PCP is a serious complication that may occur early in the course of infliximab therapy in patients with RA and physicians need to be aware of the possibility of PCP developing during inflixIMab therapy.